Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndrome

References

• Janiga J, Kentley J, Nabhan C, et al. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome. Leuk Lymphoma. 2018;59:562–577.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. Jco. 2015;33:3766–3773.
   PubMed Web of Science ®Google Scholar
• Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sézary syndrome. Jama. 1992;267:1354–1358.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. Jco. 2016;34:2698–2704.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer-response. Clin Cancer Res. 2013;19:5542.
   PubMed Web of Science ®Google Scholar
• Xia Y, Medeiros LJ, Young KH. Immune checkpoint blockade: releasing the brake towards hematological malignancies. Blood Rev. 2016;30:189–200.
   PubMed Web of Science ®Google Scholar
• Cetinozman F, Jansen PM, Vermeer MH, et al. Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides. Arch Dermatol. 2012;148:1379–1385.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Leung S, Myskowski PL, et al. Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile. Cancer Immunol Res. 2018; 8:900–909.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Kos FJ, He TF, et al. Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab. Oncoimmunology. 2017;6:e1363138.
   PubMed Web of Science ®Google Scholar
• Wartewig T, Kurgyis Z, Keppler S, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552:121–125.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
   PubMed Web of Science ®Google Scholar
• Derre L, Rivals JP, Jandus C, et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest. 2010;120:157–167.
   PubMed Web of Science ®Google Scholar
• Quan L, Lan X, Meng Y, et al. BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints. Exp Hematol. 2018;60:47–56.e1.
   PubMed Web of Science ®Google Scholar
• Yuan B, Zhao L, Fu F, et al. A novel nanoparticle containing MOG peptide with BTLA induces T cell tolerance and prevents multiple sclerosis. Mol Immunol. 2014;57:93–99.
   PubMed Web of Science ®Google Scholar
• Nakagomi D, Suzuki K, Hosokawa J, et al. Therapeutic potential of B and T lymphocyte attenuator expressed on CD8+ T cells for contact hypersensitivity. J Invest Dermatol. 2013;133:702–711.
   PubMedGoogle Scholar
• Sawaf M, Fauny JD, Felten R, et al. Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4 + T cells. JCI Insight. 2018;3:e99711.
   PubMed Web of Science ®Google Scholar
• Liu X, Alexiou M, Martin-Orozco N, et al. Cutting edge: a critical role of B and T lymphocyte attenuator in peripheral T cell tolerance induction. J Immunol. 2009;182:4516–4520.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Huang ZL, He M, et al. BTLA identifies dysfunctional PD-1-expressing CD4(+) T cells in human hepatocellular carcinoma. Oncoimmunology. 2016;5:e1254855.
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11:39.
   PubMed Web of Science ®Google Scholar
• Goldberg MV, Drake CG. LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol. 2011;344:269–278.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989–1004.
   PubMed Web of Science ®Google Scholar
• Wierz M, Pierson S, Guyonnet L, et al. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood. 2018;131:1617–1621.
   PubMed Web of Science ®Google Scholar
• Berrien-Elliott MM, Jackson SR, Meyer JM, et al. Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res. 2013;73:605–616.
   PubMed Web of Science ®Google Scholar
• Blake SJ, Dougall WC, Miles JJ, et al. Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy. Clin Cancer Res. 2016;22:5183–5188.
   PubMed Web of Science ®Google Scholar
• Baumeister SH, Freeman GJ, Dranoff G, et al. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34:539–573.
   PubMed Web of Science ®Google Scholar
• Joller N, Lozano E, Burkett PR, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40:569–581.
   PubMed Web of Science ®Google Scholar
• Kourepini E, Paschalidis N, Simoes DC, et al. TIGIT enhances antigen-specific Th2 recall responses and allergic disease. JI. 2016;196:3570–3580.
   Google Scholar
• Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10:48–57.
   PubMed Web of Science ®Google Scholar
• Chauvin JM, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest. 2015;125:2046–2058.
   PubMed Web of Science ®Google Scholar
• Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26:923–937.
   PubMed Web of Science ®Google Scholar
• Catakovic K, Gassner FJ, Ratswohl C, et al. TIGIT expressing CD4 + T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. Oncoimmunology. 2018;7:e1371399.
   PubMed Web of Science ®Google Scholar
• Guillerey C, Harjunpaa H, Carrie N, et al. TIGIT immune checkpoint blockade restores CD8(+) T cell immunity against multiple myeloma. Blood. 2018;132:1689–1694.
   Web of Science ®Google Scholar
• Kong Y, Zhu L, Schell TD, et al. T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in aml patients. Clin Cancer Res. 2016;22:3057–3066.
   PubMed Web of Science ®Google Scholar
• Polson AG, Zheng B, Elkins K, et al. Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol. 2006;18:1363–1373.
   PubMed Web of Science ®Google Scholar
• Won WJ, Foote JB, Odom MR, et al. Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cells. J Immunol. 2006;177:6815–6823.
   PubMed Web of Science ®Google Scholar
• Bin Dhuban K, d'Hennezel E, Nashi E, et al. Coexpression of TIGIT and FCRL3 identifies Helios + human memory regulatory T cells. J Immunol. 2015;194:3687–3696.
   PubMed Web of Science ®Google Scholar
• Dulphy N, Berrou J, Campillo JA, et al. NKG2D ligands expression and NKG2D-mediated NK activity in Sezary patients. J Invest Dermatol. 2009;129:359–364.
   PubMed Web of Science ®Google Scholar
• Jariwala N, Benoit B, Kossenkov AV, et al. TIGIT and helios are highly expressed on CD4+ T cells in Sézary syndrome patients. J Invest Dermatol. 2017;137:257–260.
   PubMed Web of Science ®Google Scholar
• Wysocka M, Kossenkov AV, Benoit BM, et al. CD164 and FCRL3 are highly expressed on CD4 + CD26- T cells in Sézary syndrome patients. J Invest Dermatol. 2014;134:229–236.
   PubMed Web of Science ®Google Scholar
• Benoit BM, Jariwala N, O’Connor G, et al. CD164 identifies CD4(+) T cells highly expressing genes associated with malignancy in Sezary syndrome: the Sezary signature genes, FCRL3, Tox, and miR-214. Arch Dermatol Res. 2017;309:11–19.
   PubMed Web of Science ®Google Scholar
• Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer. 2017;77:57–74.
   PubMed Web of Science ®Google Scholar
• Braumuller H, Wieder T, Brenner E, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013;494:361–365.
   PubMed Web of Science ®Google Scholar
• Wolk K, Mitsui H, Witte K, et al. Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function. Clin Cancer Res. 2014;20:5507–5516.
   PubMed Web of Science ®Google Scholar
• Guenova E, Watanabe R, Teague JE, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res. 2013;19:3755–3763.
   PubMed Web of Science ®Google Scholar
• Rubio Gonzalez B, Zain J, Rosen ST, et al. Tumor microenvironment in mycosis fungoides and Sézary syndrome. Curr Opin Oncol. 2016;28:88–96.
   PubMed Web of Science ®Google Scholar
• Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. Immunology. 2010;129:474–481.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486–499.
   PubMed Web of Science ®Google Scholar
• Catakovic K, Klieser E, Neureiter D, et al. T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signal. 2017;15:1.
   PubMed Web of Science ®Google Scholar
• Kasakovski D, Xu L, Li Y. T cell senescence and CAR-T cell exhaustion in hematological malignancies. J Hematol Oncol. 2018;11:91.
   PubMed Web of Science ®Google Scholar
• Wang M, Bu J, Zhou M, et al. CD8 + T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clin Immunol. 2018;190:64–73.
   PubMed Web of Science ®Google Scholar
• Torrealba MP, Manfrere KC, Miyashiro DR, et al. Chronic activation profile of circulating CD8 + T cells in Sezary syndrome. Oncotarget. 2018;9:3497–3506.
   PubMedGoogle Scholar
• Campbell JJ, Clark RA, Watanabe R, et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767–771.
   PubMed Web of Science ®Google Scholar
• Spodzieja M, Lach S, Iwaszkiewicz J, et al. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses. PLoS One. 2017;12:e0179201.
   PubMed Web of Science ®Google Scholar